ClinicalTrials.gg

Program

Celecoxib

Also written as “celecoxib”, “Celecoxib 200mg” and “Celecoxib + Acetaminophen”.

Its studies are mostly in Osteoarthritis · Osteoarthritis, Knee · Low Back Pain · Migraine Disorders · Pain, Postoperative, led by 16 companies.

Furthest: phase 4, since Aug 26, 200566 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris320 open or runningphase 4since Aug 26, 2005Aug 26, 2005none ahead
Pfizer100 open or runningphase 4since Sep 9, 2005May 8, 2002none ahead
Dr. Reddy's Laboratories40 open or runningphase 2since Jun 8, 2015Jun 8, 2015none ahead
NeuroSense Therapeutics40 open or runningphase 2since Nov 13, 2019Aug 29, 2019none ahead
Leidos Life Sciences30 open or runningphase 2since Oct 7, 2021Oct 7, 2021none ahead
BioDelivery Sciences International20 open or runningphase 3since Dec 27, 2016Dec 27, 2016none ahead
Laboratorios Silanes S.A. de C.V.20 open or runningphase 3since Jun 26, 2024Jun 26, 2024none ahead
Aralez Pharmaceuticals10 open or runningphase 1since Aug 5, 2008Aug 5, 2008none ahead
arthritis-innovation-corporation10 open or runningphase 2since May 8, 2018May 8, 2018none ahead
Astellas Pharma10 open or runningphase 3since May 5, 2010May 5, 2010none ahead
Bausch Health Companies10 open or runningphase 3since Jul 3, 2006Jul 3, 2006none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 4since Feb 3, 2017Feb 3, 2017none ahead
Dong-A ST10 open or runningphase 4since May 19, 2016May 19, 2016none ahead
kitov-pharmaceuticals-ltd10 open or runningphase 3since Jun 20, 2014Jun 20, 2014none ahead
Mundipharma10 open or runningphase 3since Feb 20, 2017Feb 20, 2017none ahead
x-pert-med-gmbh10 open or runningphase 1since Nov 9, 2009Nov 9, 2009none ahead

Also a collaborator on its studies: AstraZeneca.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Aug 29, 2005.

  1. Dec 27, 2016BioDelivery Sciences International's first studies: 2 phase 3 studies in Migraine DisordersNew to BioDelivery Sciences InternationalBioDelivery Sciences International · NCT03009019, NCT03006276
  2. Feb 3, 2017Chong Kun Dang Pharmaceutical's first study: phase 4 study in Osteoarthritis HandNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03067194 · 117 enrolled · Korea, Republic of
  3. Feb 7, 2017Phase 1 study in HealthyDr. Reddy's Laboratories · NCT03051685 · 16 enrolled · United States
  4. Feb 20, 2017Mundipharma's first study: phase 3 study in Acute PainNew to MundipharmaMundipharma · NCT03062644 · 1,138 enrolled · Belarus, Bulgaria, Canada and more
  5. Aug 17, 2017Phase 1 study in Migraine DisordersDr. Reddy's Laboratories · NCT03282838 · 24 enrolled · United States
  6. May 8, 2018arthritis-innovation-corporation's first study: phase 2 study in Pain, PostoperativeNew to arthritis-innovation-corporationarthritis-innovation-corporation · NCT03541655 · 20 enrolled · United States
  7. May 21, 2018Phase 2 study in Acute PainDr. Reddy's Laboratories · NCT03554772 · 120 enrolled · United States
  8. Aug 29, 2019NeuroSense Therapeutics's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to NeuroSense TherapeuticsNeuroSense Therapeutics · NCT04090684 · 10 enrolled · United States
  9. Nov 13, 2019Phase 2 study in Amyotrophic Lateral SclerosisNeuroSense Therapeutics · NCT04165850 · 16 enrolled · Israel
  10. Oct 7, 2021Leidos Life Sciences's first studies: 3 phase 2 studies in COVID-19New to Leidos Life SciencesLeidos Life Sciences · NCT05085574, NCT05077969, NCT05077332
  11. Jan 19, 2022Phase 1 study in PharmacokineticsNeuroSense Therapeutics · NCT05232461 · 12 enrolled · United States
  12. Jun 22, 2022Phase 1 study in PharmacokineticsNeuroSense Therapeutics · NCT05436678 · 19 enrolled · United States
  13. Jun 26, 2024Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in Low Back PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT06516094 · 192 enrolled · Mexico
  14. Mar 3, 2025Phase 3 study in ArthralgiaLaboratorios Silanes S.A. de C.V. · NCT06863636 · 231 enrolled · Mexico

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
MeloxicamruleBoehringer Ingelheimphase 467
EtoricoxibruleOrganonphase 435
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06863636Arthralgia · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Oct 30, 2025231
NCT06516094Low Back Pain · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Jan 1, 2025192
NCT05436678Pharmacokinetics · United States1CompletedNeuroSense TherapeuticsAug 19, 202219
NCT05232461Pharmacokinetics · United States1CompletedNeuroSense TherapeuticsApr 21, 202212
NCT05085574COVID-192WithdrawnLeidos Life SciencesFeb 7, 20230
NCT05077969COVID-19 · United States2TerminatedLeidos Life SciencesJun 28, 20224
NCT05077332COVID-19 · United States2CompletedLeidos Life SciencesNov 10, 20254
NCT04165850Amyotrophic Lateral Sclerosis · Israel2CompletedNeuroSense TherapeuticsJan 19, 202116
NCT04090684Amyotrophic Lateral Sclerosis · United States1CompletedNeuroSense TherapeuticsSep 27, 202110
NCT03554772Acute Pain · United States2CompletedDr. Reddy's LaboratoriesAug 20, 2018120
NCT03541655Pain, Postoperative · United States2Completedarthritis-innovation-corporationJun 20, 201920
NCT03282838Migraine Disorders · United States1CompletedDr. Reddy's LaboratoriesAug 22, 201724
NCT03062644Acute Pain · Belarus, Bulgaria, Canada and more3CompletedMundipharmaJun 29, 20181,138
NCT03051685Healthy · United States1CompletedDr. Reddy's LaboratoriesAug 14, 201516
NCT03067194Osteoarthritis Hand · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalJul 10, 2017117
NCT03009019Migraine Disorders · United States3CompletedBioDelivery Sciences InternationalNov 2017631
NCT03006276Migraine Disorders · United States3CompletedBioDelivery Sciences InternationalNov 2017622
NCT02780323Arthritis, Rheumatoid · Korea, Republic of4CompletedDong-A STDec 26, 2017119
NCT02472418Migraine Disorders · United States2CompletedDr. Reddy's LaboratoriesDec 1, 201563
NCT02172040Hypertension · United Kingdom3Completedkitov-pharmaceuticals-ltdNov 19, 2015152
NCT01838044Chronic Low Back Pain With a Neuropathic Component · Brazil, Chile, Colombia and more4TerminatedViatrisMay 2015180
NCT01118572Pain, Postoperative · Japan3CompletedAstellas PharmaNov 2010616
NCT01062113Pain · Japan2CompletedViatrisAug 2010255
NCT01020279Musculoskeletal Pain · Germany1Completedx-pert-med-gmbh82
NCT00994461Healthy Volunteers · Japan4CompletedViatrisApr 2010190
NCT00976716Pain · Japan3CompletedViatrisNov 200980
NCT00894790Pain · Mexico4TerminatedViatrisJan 20108
NCT00807846Arthritis, Juvenile · United States, Chile, Costa Rica and more4CompletedViatrisDec 2012201
NCT00762463Spondylitis, Ankylosing · China3CompletedViatrisJun 2010240
NCT00729495Healthy Volunteer · United States1CompletedAralez PharmaceuticalsAug 200880
NCT00663767Toothache · United States2CompletedPfizerJun 20, 2008250
NCT00652925Arthritis, Juvenile · United States, Belgium, Brazil and more3CompletedPfizerApr 2004225
NCT00648141Spondylitis, Ankylosing · Germany3CompletedPfizer458
NCT00643799Osteoarthritis, Knee · United States4CompletedViatrisJan 2005586
NCT00640809Inflammatory Bowel Diseases · United States4CompletedViatris408
NCT00640627Osteoarthritis, Knee · United States4CompletedViatris380
NCT00640432Low Back Pain · Brazil4CompletedViatris244
NCT00639483Schizophrenia · Argentina, Brazil, Germany and more2CompletedPfizer270
NCT00638807Osteoarthritis, Knee · United States4CompletedViatris388
NCT00633438Arthroscopy · United States4CompletedViatris204
NCT00633386Arthroscopy · United States4CompletedViatris200
NCT00630929Osteoarthritis, Knee · Germany, Spain, United Kingdom4CompletedViatris388
NCT00620867Osteoarthritis, Knee · United States4CompletedViatrisMar 2003393
NCT00585312Adenomatous Polyposis Coli · United States, Belgium, Czechia and more3TerminatedViatrisOct 2013106
NCT00662558Low Back Pain · United States3CompletedViatrisSep 2008802
NCT00549549Arthritis, Gouty · United States, Canada, Colombia and more3CompletedViatrisDec 2009402
NCT00484718Osteoarthritis · United States4TerminatedPfizerJun 10, 20096
NCT00446797Ankle Injuries · Brazil, Costa Rica, Ecuador and more4CompletedViatrisApr 2008278
NCT00402987Pharyngitis · United States3CompletedViatrisNov 15, 2007269
NCT00373685Osteoarthritis · United States, Puerto Rico4CompletedViatrisNov 20108,067
NCT00359151Osteoarthritis · United States4TerminatedViatris22
NCT00348452Chronic Pain3CompletedBausch Health Companies1,000
NCT00346216Arthritis, Rheumatoid · United States, Australia, Brazil and more4CompletedViatrisApr 12, 201624,081
NCT00296127Healthy Volunteers · United States1CompletedViatris24
NCT00290901Back Pain · United States, Puerto Rico4CompletedViatrisDec 2006754
NCT00174317Osteoarthritis, Hip · United Kingdom4CompletedPfizer250
NCT00163241Osteoarthritis · Canada, France3TerminatedViatris666
NCT00150280Pain, Postoperative · China3CompletedViatris132
NCT00141154Low Back Pain · Japan3CompletedViatris1,234
NCT00141102Osteoarthritis · Belgium, Brazil, Canada and more4CompletedViatrisMay 20094,484

How it is read

Names in the registry

  • “Celecoxib”, 49 entries
  • “celecoxib”, 7 entries
  • “Celecoxib 200mg”, 3 entries
  • “Celecoxib + Acetaminophen”, 2 entries
  • “Comparator: celecoxib”, 2 entries

Codes read as this program: DFN15.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.